Skip to main content
SpringerLink
Log in

GnRH-Antagonisten bei PCa-Patienten mit klinisch relevanter kardiovaskulärer Vorerkrankung

GnRH agonist in PCa patients with clinically significant pre-existing cardiovascular disease

  • Leserbriefe
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Böhmer D, Wirth M, Miller K et al (2016) Radiotherapy and hormone treatment in prostate cancer – the use of combined percutaneous radiotherapy and hormonal ablation to manage in situ and locally spread tumors. Dtsch Ärztebl Int 113:235–241

    PubMed  PubMed Central  Google Scholar 

  2. British Uro-Oncology Group (2014) Re: Final Appraisal Determination – Appeal Against FAD – Degarelix for treating advanced hormone-dependent prostate cancer. Recipient: Dr. Margaret Helliwell. In, NICE National Institute for Health and Care Excellence

  3. Knutsson A, Hsiung S, Celik S et al (2016) Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. Sci Rep 6:26220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kunath F, Borgmann H, Blumle A et al (2015) Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer. A systematic review with meta-analysis. BMJ Open 5:e008217

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ruessel C, Walker J, Jacob J et al (2016) Androgen Deprivation Therapy (ADT) and Cardiovascular Risk: Analysis of German Statutory Health Insurance (SHI) data. J Clin Oncol 34(suppl 2 S):abstr 232–2016 (ASCO-GU 2016 Genitourinary Cancers Symposium, San Francisco)

    Google Scholar 

  6. Tschöpe C, Kherad B, Spillmann F et al (2016) Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer: Differences between GnRH antagonists and GnRH agonists. Herz. 2016 Apr 15 [Epub ahead of print]

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, Universitätsklinikum Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Deutschland

    A. Merseburger

  2. Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover (MHH), Hannover, Deutschland

    D. Sedding

Authors
  1. A. Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Sedding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Merseburger.

Ethics declarations

Interessenkonflikt

Professor Axel S. Merseburger: Referenten-, Berater-, Studientätigkeit für Ipsen, Bayer, Pfizer, Novartis, Astellas, Hexal, Ferring, Janssen Cilag, Roche, Wyeth, TEVA, Oncogenex, Medivation. Prof. Daniel Sedding: Referenten-, Berater-, Studientätigkeit für Bayer, Pfizer, Novartis, Ferring, Boehringer Ingelheim, Lilly, Servier, AstraZeneca, Biotronic, Medtronic, Abbott, Berlin Pharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Merseburger, A., Sedding, D. GnRH-Antagonisten bei PCa-Patienten mit klinisch relevanter kardiovaskulärer Vorerkrankung. Urologe 55, 1240–1241 (2016). https://doi.org/10.1007/s00120-016-0197-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-016-0197-z

Search

Navigation